Recent understanding in the treatment of visceral leishmaniasis

Journal of Postgraduate Medicine

Volumn 49, Issue 1, 2003, Pages 61-68

  Rosenthal, Eric ^a   Marty, P ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Amphotericin B; Developing countries; Drug resistance; HIV; Liposomal amphotericin B; Miltefosine; Pentavalent antimonials

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; COMBINOPHARM; DIAMIDINE DERIVATIVE; FLUCONAZOLE; GAMMA INTERFERON; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; METRONIDAZOLE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; SITAMAQUINE; STIBOGLUCONATE SODIUM; TERBINAFINE; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ANTIPROTOZOAL ACTIVITY; BONE PAIN; CHILL; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGLYCEMIA; KIDNEY FAILURE; LEISHMANIA; LIVER DYSFUNCTION; MYALGIA; NAUSEA; NEPHROTOXICITY; OPTIMAL DRUG DOSE; OTOTOXICITY; PSYCHODIDAE; REPRODUCTIVE TOXICITY; REVIEW; VISCERAL LEISHMANIASIS; VOMITING;

EID: 0037869067     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: 10.4103/0022-3859.926     Document Type: Review

References (79)

1. Desjeux P. The increase in risk factors of leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001;95:239-43.
2. Seaman J, Mercer AJ, Sandorp E. The epidemic of visceral leishmaniasis of Upper Nile, Southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 1996;25:862-71.
3. WHO: Leishmania/HIV co-infection, South-western Europe 1990-1998. Geneva: World Health Organization; mimeographed document 2000 WHO/LEISH/2000.42.
4. WHO. Report of the consultative meeting on Leishmania/HIV coinfection, Rome, 6-7 Setember, 1994. Geneva: World Health Organization; mimeographed document 1995 WHO/LEISH/95.35/1995.
5. Rosenthal E, Marty P, Poizot-Martin, Reynes J, Pratlong F, Lafeuillade A et al. Visceral leishmaniasis and HIV-1 co-infection in Southern France. Trans R Soc Trop Med Hyg 1995;89:159-62.
6. Wolday D, Berhe N, Akuffo H, Britton S. Leishmania/HIV interaction: immunopathogenic mechanisms. Parasitol Today 1999;15:182-7.
7. Rosenthal E, Marty P, Del Giudice P, Pradier C, Ceppi C, Gastaut JA, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 2000;31: 1093-5.
8. Rosenthal E, Tempesta S, Del Giudice P, Marty P, Pradier C, Le Fichoux Y. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS 2001;15:84-5.
9. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306.
10. Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infec Dis 1988;10:560-.86.
11. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of indian epidemic. Clin Infect Dis 2000;31:1104-6.
12. Thakur CP. Sodium antimony gluconate, amphotericin, and myocardial damage. Lancet 1998;351:1928-9.
13. Santos J, Rivero A, Marquez M. Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection. An Med Interna 2000;7:562-3.
14. Veeken H, Ritmeijer K, Seaman J, Davidson R. Randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000;5:312-7.
15. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, et al. Ethiopian visceral leishmaniasis: generic and propriarity sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Med Hyg 2001;95:668-72.
16. Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, et al. Comparison of generic and propiarity sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001;79:388-93.
17. Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 1998;59:139-43.
18. Frezard F, Michalick MS, Soares CF, Demicheli C. Novel methods for the encapsulation of meglumine antimoniate into liposomes. Braz J Med Biol Res 2000;33:841-6.
19. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992;340: 1256-7.
20. Das VN, Ranjan A, Sinha AN, Verma N, Lal CS, Gupta AK, et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc Physicians India 2001;49:609-13.
21. Seaman J, Pryce D, Sondorp H, Wilkinson R, Bryceson ADM. Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1994;168:715-20.
22. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro PA. prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000;94:429-31.
23. Thakur CP, Kanyok TP, Pandey AK, Sinha GP Messick C, Olliaro P. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 2000;94:432-3.
24. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001;45:2185-97.
25. Kager PA, Rees PH, Wellde BT, Hockmeyer WT, Lyverly WH. Al-66 lopurinol in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1981;75:556-9.
26. Chunge CN, Gachihi G, Muigai R. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg 1985;79:715-8.
27. Jha TK. Evaluation of allopurinol in the treatment of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983;77:204-7.
28. Ragusa R, Di Cataldo A, Samperi P Schiliro, G. Treatment of visceral leishmaniasis with meglumine and allopurinol. Am J Dis Child 1993;147:611-2.
29. Thakur CP Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999;93:319-23.
30. Sundar S, Gupta LB, Rastogi V, Agrawall G, Murray HW. Short course, cost-effective treatment with Amphotericin B-fat emulsion cures visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000;94:2004
31. Davidson RN, Croft SL, Scott A, Maini M, Moody AH, Bryceson ADM. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 1991;337:1061-2.
32. Davidson RN, Di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22:938-43.
33. Dietze R, Fagundes SMS, Brito EF, Milan EP, Feitosa TF, Suassuna FA, et al. Treatment of kala azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995; 89:309-11.
34. Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex (ABLC). J Infect Dis 1996;173:762-6.
35. Sundar S, Agrawall G, Sinha PR, Horwith GS, Murray HW. Short course low-dose amphotericin B lipid complex therapy for visceral leishmaniasi unresponsive to antimony. Ann Intern Med 1997;127:133-7.
36. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996;90:319-22.
37. Gradoni L. Chemotherapy of leishmaniasis and trypanosomiasis: advances and failures. Curr Opin Infect Dis 1996;9:435-8.
38. Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9.
39. Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Caldeira L, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infection 1996;32:133-7.
40. Torre-Cisneros J, Villanueva JL, Kindellan JM, Jurado R, Sanchez-Guijo P. Successful treatment of antimony resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis 1993;17:625-7.
41. Boletis JN, Pefanis A, Stathakis C, Helioti H, Kostakis A, Giamarellou H. Visceral leishmaniases in renal transplant recipients: successful treatment with liposomal amphotericin B (Ambisome). Clin Infect Dis 1999;28:1308-9.
42. Sundar S, Agrawall G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal ampholtericin B randomized trial. BMJ 2001;323:419-22.
43. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 1987;36:2633-6.
44. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992;36:1630-4.
45. Le Fichoux Y, Rousseau D, Ferrua B, Ruette S, Lelievre A, Grousson D, et al. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in Balb/c mice. Antimicrob Agents Chemother 1998;42:654-8.
46. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996;38: 1041-7.
47. Urbina JA. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 1997;114(Suppl):S91-S9.
48. Murray HW, Delph-Etienne S. Visceral leishmanicidal activity of hexaclecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis 2000; 181:795-9.
49. Murray HW, Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun 2000;68:288-93.
50. Murray HW. Suppression of posttreatment recurrence of experimental visceral. leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother 2000;44:3235-6.
51. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998;352:1821-3.
52. Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999;93:589-97.
53. Jha TK, Sundar S, Thakur TP. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999;341:1795-800.
54. Sundar S, Makharia MK, More DK, Agrawal G, Voss A, Fischer C, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000;31:1110-3.
55. Sundar S, Jha TK, Thakur CP Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for indian leishmanisis. N Engl J Med 2002;347:1739-46.
56. Berman JD. Human leishmaniasis:clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703.
57. Gangneux JR Données récentes sur le traitement de la leishmaniose viscérale. Presse Med 1999;28:2057-66.
58. Murray HW. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int J Infect Dis 2000;4:158-77.
59. Sherwood JA, Gachihi GS, Muiggai RK, Skillman DR, Mugo M, Rashid JR, et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994; 19:1034-9.
60. Dietze R, Carvalho SF, Valli LC, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001;65:685-9.
61. Murray HW, Granger AM, Mohanty SK. Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma and interleukin-2-independent. J Infect Dis 1991;163: 622-4.
62. Sundar S, Murray HW. Effect of treatment with interferon-gamma alone in visceral leishmaniasis. J Infect Dis 1995;172:1627-9.
63. Badaro R, Falcoff E, Badarc, FS, Carvalho EM, Pedral-Sampaio D, Barral A, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990;322:16-21.
64. Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-gamma plus pentavalent antimony in hidian visceral leishmaniasis. J Infect Dis 1997;176:1117-9.
65. Harrat Z, Addadi K, Belkaid M, Tabet-Derraz O. La leishmaniose viscérale en Algérie. Recensement des cas de leishmaniose viscérale. Bull Soc Path E 1992;85:296-301.
66. Marty P, Le Fichoux. Y, Pratlong F, Gari-Toussaint M. Human visceral leishmaniasis in Alpes-Maritimes, France: epidemiological characteristics for the period 1985-1992. Trans R Soc Trop Med Hyg 1994;88:33-4.
67. Alvar J, Canavate C, Gutirrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, et al. Leishmania and human immunodeficiency virus coinfection: the first ten years. Clin Microbiol Rev 1997;10:298-319.
68. Kubar J, Marty P, Lelievre A, Quaranta JF, Staccini P, Caroli-Bosc C, et al. Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+T-lymphocyte counts. AIDS 1998;12:2147-53.
69. Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Laboz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000;14:383-6.
70. Berenguer J, Cosin J, Miralles P, Lopez JC, Padilla B. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 2000;14:2946-58.
71. Thakur CP. Epidemiological, clinical and therapeutic features of kalaazar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 1984;78:391-8.
72. Gradoni L, Bryceson A, Desjeux P. Treatment of mediterranean visceral leishmaniasis. Bull World Health Organization. 1995;73:191-7.
73. Anonymous. Conclusions and recommendations of the IVth WHO joint meeting on Leishmania-HIV co-infections. Parasite 2001;8: 376-9.
74. Laguna F, Lopez-Velez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999;13:1063-9.
75. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organization 1998; 76:25-32.
76. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001;6:849-54.
77. Marty P, Rosenthal E. Treatment of visceral leishmaniasis: a review of current treatment practices. Expert Opin Pharmacother 2002;3:1101-8.
78. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001;6:928-93.
79. Murray HW. Kala-azar-Progress against a neglected disease. N Engl J Med 2002;347:1793-4.